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Background: The arterial system in diabetic patients is characterized by generalized non-atherosclerotic alterations
in the vascular extracellular matrix causing increased arterial stiffness compared with subjects without diabetes. The
underlying pathophysiology remains elusive. The elastin-associated extracellular matrix protein, fibulin-1, was
recently found in higher concentrations in the arterial wall and in plasma in patients with long duration type 2
diabetes. Furthermore, plasma fibulin-1 independently predicted total mortality and was associated with pulse
pressure, an indirect measure of arterial stiffness. Whether plasma fibulin-1 is associated with arterial stiffness at
earlier phases of type 2 diabetes has not been determined.
Methods: In this cross-sectional study, we examined 90 patients with recently diagnosed type 2 diabetes
(< 5 years) and 90 gender- and age-matched controls. Plasma fibulin-1 was measured immunochemically. Arterial
stiffness was assessed by carotid-femoral Pulse Wave Velocity (PWV). Differences in means were assessed by t-tests.
Associations were assessed by multivariate regression analyses.
Results: Plasma fibulin-1 levels were lower in the diabetic group compared with the control group, 93 ± 28 vs
106 ± 30 μg/mL, p = 0.005. In unadjusted analysis of the total study sample, plasma fibulin-1 was not associated
with PWV, p = 0.46. However, with adjustment for the confounders age, gender, mean blood pressure, heart rate,
body mass index, diabetes and glomerular filtration rate, a 10 μg/mL increase in plasma fibulin was associated with
0.09 ± 0.04 m/s increase in PWV, p < 0.05. In subgroup analysis, plasma fibulin-1 was associated with PWV in the
diabetes group, (0.16 ± 0.07 m/s increase in PWV per 10 μg/mL increase in plasma fibulin-1, p<0.05), but not
controls, β = 0.021 ± 0.057 m/s per 10 μg/mL, p = 0.70. The association remained significant in the diabetes group
after adjustment for covariates, p < 0.05.
Conclusions: Plasma fibulin-1 is independently associated with PWV. Yet, as the plasma level of fibulin-1 was lower
in patients with recently diagnosed type 2 diabetes than in healthy controls, plasma fibulin-1 levels are not a simple
marker of the degree of arterial stiffening. Further studies are needed to determine the exact role of fibulin-1 in
arterial stiffness and cardiovascular risk in patients with type 2 diabetes.
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Despite the intensified blood pressure and cholesterol
treatment during the previous decades, type 2 diabetes
(T2DM) remains associated with an increased risk of
fatal and non-fatal cardiovascular disease (CVD) [1,2].
The pathophysiological processes underlying this associ-
ation remains elusive. Arterial wall stiffness may be a
contributing factor. Arterial stiffness has been shown to
predict cardiovascular disease [3] and the vascular sys-
tem in patients with type 2 diabetes is characterized by
an increased stiffness of the arterial wall compared to
subjects without diabetes [4]. The pathophysiology un-
derlying the increased arterial stiffening seen in diabetes
patients probably involves changes in structure and
amount of extracellular matrix (ECM) molecules in the
media layers of the arteries, including collagens and
elastin [5-10], but remains overall incompletely under-
stood. Interestingly, the elastin-associated ECM mol-
ecule fibulin-1 was recently identified in non-
atherosclerotic arterial tissue from patients with type 2
diabetes [11]. The fibulin-1 protein was found in higher
concentration in the arterial wall and in plasma from pa-
tients with type 2 diabetes with long diabetes duration
and CVD, compared with non-diabetics with CVD [11].
Moreover, in T2DM patients with longstanding disease,
fibulin-1 was associated with pulse pressure, an indirect
measure of arterial stiffness, and independently pre-
dicted total mortality during 15 years of follow-up [11].
Fibulin-1 levels in recently diagnosed T2DM patients
have not yet been described.
Carotid-femoral pulse wave velocity (PWV) is consi-
dered the gold standard for non-invasive assessment of
arterial stiffness [3]. Increased PWV is independently
associated with cardiovascular morbidity and mortality
in both low- and high-risk non-diabetic populations
[12-18] and predicts cardiovascular and total mortality
in patients with type 2 diabetes [19]. The association be-
tween fibulin-1 and PWV in patients with type 2 dia-
betes remains to be elucidated.
Thus, in this study we sought to i) compare the
plasma-fibulin-1 levels in patients with recently diag-
nosed type 2 diabetes with a gender- and age-matched
control group and ii) to study the association between
plasma fibulin-1 levels and PWV.
Subjects and methods
100 patients with type 2 diabetes and 100 controls mat-
ched individually for gender and age were included in
the present study. The study protocol has been described
in detail elsewhere (Clinical Trials no NCT00674271).
Briefly, the patients were consecutively recruited from the
outpatient clinic at Aarhus University Hospital, Denmark.
Inclusion criteria were age >18 years, diagnosis of type 2
diabetes according to WHO criteria [20] and knownduration of diabetes < 5 years. The control subjects were
recruited by advertising in the local press and matched
consecutively by gender and age to the diabetes patients.
Undiagnosed diabetes was excluded by fasting glucose and
oral glucose tolerance test. Subjects with impaired fasting
glucose (9 participants) or impaired glucose tolerance
(3 participants) or both (2 participants) were accepted as
control subjects. Exclusion criteria for both patients with
diabetes and controls were acute or chronic infectious dis-
ease, end-stage renal failure, pregnancy or lactation, prior
or present cancer and contraindications to magnetic res-
onance imaging (MRI) (claustrophobia, magnetic material
in the body and body weight >120 kg). History of hyper-
tension or cardiovascular disease were not exclusion crite-
rions. PWV data were not recordable in 4 patients owing
to atrial fibrillation, in 3 patients owing to obesity and in 2
patients owing to technical problems. Fibulin-1 data was
not available in one patient due to technical problems
(only a minor quantity of blood could be drawn from the
patient, insufficient for analysis beyond baseline data). The
10 matches for these 10 participants were also excluded;
thus, data from 180 participants were available for statis-
tical analysis. The study was approved by the Research
Ethics Committee of Central Region, Denmark and by the
Danish Data Protection Agency. All patients gave their
written informed consent to participate.
Biochemical analysis
Fibulin-1 was analyzed with a sandwich immunoassay
[11] modified from a previously described method [21].
Briefly, 96-wells were coated with 3 μg/ml rabbit anti
human fibulin-1 IgG (Rb 2954 IgG) and blocked with
3 mg/ml BSA in TBS. Plasma samples, diluted 1/1.000,
were added to wells for 2 hours, washed and anti-human
fibulin-1 IgG (mouse monoclonal, 3A11) applied and in-
cubated for 2 hours at room temperature. Detection of
bound secondary antibody was done with rabbit anti
mouse-IgG (AD0124, PerkinElmer), labeled with Euro-
pium (Eu). Bound Eu was detected using time-resolved
fluorescence on DELFIA (Perkin Elmer). A standard
curve (ranging from 0.01-0.32 μg protein/ml) was
generated using purified human fibulin-1. The linear-
ity of the immunoassay was tested using two plasma
samples, diluted from 1/200 to 1/2,000. Interassay varia-
tion was ~10%.
Pulse wave velocity measurements
Examinations were conducted between 9 a.m. and 1 p.m.
after a minimum of 5 minutes rest in a quiet room. The
study subjects had abstained from smoking and intake
of tea, coffee or other caffeine-containing beverages
for at least 3 hours prior to the examinations. At
least two hours elapsed between breakfast and the
examinations.
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planation tonometer (Millar, SPT-301B, Houston, Texas,
USA) and SphygmoCor equipment and software, version
8.0 (AtCor Medical, Sydney, Australia). After a mini-
mum of 5 minutes of rest in the supine position, the
carotid-femoral PWV was determined by sequential
ECG referenced recordings of the pulse wave at the ca-
rotid and the femoral artery by the tonometer. The tran-
sit time was determined by the intersecting tangent
algorithm method [22] and the path length calculated by
subtracting the distance between the carotid artery
measurement site and sternal notch from the distance
between the femoral artery site and the sternal notch
[3], all measured directly by a tape measure. The mean
of two PWV measurements was calculated for each pa-
tient. Within-subject coefficient of variation for PWV
was 5.1%.
Office blood pressure (BP) was measured on the right
arm, and mean systolic and diastolic BP were calculated
as the average of 3 measurements obtained after a mi-
nimum of 5 minutes of rest in the seated position. BP
was measured by a Riester Champion N automatic
blood pressure monitor (Riester GmbH, Jungingen,
Germany) or a Speidel&Keller mercury sphygmomano-
meter (Speidel&Keller, Welch Allyn, Jungingen, Germany).
Pulse pressure (PP) was calculated as systolic BP minus
diastolic BP, and mean arterial pressure (MAP) as diastolic
BP + ((systolic minus diastolic BP)/3).
24-h Ambulatory BP monitoring (ABPM) was per-
formed using Spacelabs 90217 (Spacelabs Healthcare,
Issaquah, Washington, USA). BP was measured with
20 minute intervals day and night. The calculation of
day and night BP was based on patients’ individual diary
recordings of awake and sleeping hours. Recordings with
more than three missing hours (maximum 1 hour during
nighttime) were excluded from the analysis.
Statistical analyses
Differences in means between the diabetes and control
group were assessed by paired t-tests. Differences within
groups were assessed by unpaired t-tests. Assumptions
of normal distributions were tested by histograms and
QQ-plots. Skewed data were log-tranformed prior to
t-tests. Baseline data are presented as mean ± SD or me-
dian (25; 75. percentile) for skewed data. Correlation
between parameters was assessed by Pearson’s correl-
ation coefficient and in regression analysis. A two-tailed
p-value of less than 0.05 was considered statistically sig-
nificant. Data were analyzed with software from Stata
(Stata 11, StataCorp LP, Texas, USA).
Results
Patient characteristics are presented in Table 1. The pa-
tients with diabetes had good glycemic control. Officesystolic and diastolic BP and lipid levels were signifi-
cantly lower in the diabetes group, probably due to the
fact that a significantly higher proportion of the diabetes
population was in antihypertensive and cholesterol low-
ering treatment compared with the control group. There
was no difference between the two groups regarding
24-h ABPM systolic and diastolic BP, whereas 24-h pulse
pressure, resting heart rate and 24-h heart rate were
higher in the diabetes group. The patients with diabe-
tes had lower creatinine levels and higher estimated
glomerular filtration rate (eGFR) and urinary albumin-
creatinine ratio compared with the control group. More-
over, carotid-femoral PWV was significantly higher in
the diabetes group. Regarding diabetes treatment, 23 pa-
tients were treated with diet only and 67 patients were
treated with one or more anti-diabetic medications. 56
(84%) of these 67 patients received metformin, 12(18%)
received sulfonylureas, 8(12%) insulin, 3(4%) dipeptidyl
peptidase-4 inhibitors, 2 (3%) glucagon-like peptide 1.
Fibulin-1 and patient characteristics
Plasma fibulin-1 was associated with estimated glo-
merular filtration rate in the diabetes group, but not
with other patient characteristics in the diabetes or con-
trol group, Table 2.
Plasma fibulin-1 levels were significantly lower in the
diabetes group than in the control group, 93 ± 28 vs
106 ± 30 μg/mL, p = 0.005, as illustrated in Figure 1A.
This association remained significant with adjustment
for glomerular filtration rate, p < 0.05. Diabetes patients
treated with metformin had significantly lower fibulin-1
levels than patients not treated with metformin, 88 ± 23
vs 103 ± 34 μg/mL, p < 0.05, despite comparable glo-
merular filtration rates, 78 ± 16 vs 75 ± 14 mL/min/
1.73 m2, p = 0.28. No association was found with other
anti-glycemic medications (i.e. sulfonylureas, insulin,
glucagon-like-peptide-1 agonists, dipeptidyl dipeptidase-
4 inhibitors) or with antihypertensive medications and
lipid-lowering medications. Patients with diabetes that
were not treated with metformin had plasma fibulin-1
levels comparable to the controls, 103 ± 34 vs. 100 ±
30 μg/mL, p = 0.75 (Figure 1B), whereas metformin-
treated patients had markedly lower fibulin-1 levels
than controls, 88 ± 23 vs. 109 ± 29 μg/mL, p < 0.001
(Figure 1C).
In the diabetes group, PWV was not significantly
lower in the patients treated with metformin compared
with those that were not, 9.0 ± 1.7 vs 9.6 ± 2.3 m/s, p =
0.14. Adjustment for age increased the p-value further,
p = 0.58.
In the control-group, women had significantly higher
plasma fibulin-1 than men, 115 ± 30 vs 97 ± 27 μg/mL,
p < 0.01, whereas in the diabetes group no gender dif-
ferences were seen, 96 ± 28 vs 91 ± 29 μg/mL (women vs
Table 1 Patient characteristics
Diabetics Controls P-value
Sex (male/female) 46/44 46/44 -
Age (years) 59 ± 10 59 ± 10 -
Diabetes duration (years) (median(IQR)) 1.9(0.8;3.2) - -
HbA1c (%) (median(IQR)) 6.5 (6.2;6.8) 5.7 (5.5;5.8) <0.001
Body Mass Index (BMI)(kg/m2) 30 ± 5 26 ± 4 <0.001
Smoking (present/previous/never) 19/33/38 19/30/41 0.88
Statins (yes/no) 70/20 16/74 <0.001
Antihypertensive treatment (yes/no) 57/33 25/65 <0.001
History of cardiovascular disease (yes/no) 17/73 10/80 <0.001
Total-cholesterol (mmol/l) 4.3 ± 0.8 5.7 ± 1.0 <0.001
LDL-cholesterol (mmol/l) 2.2 ± 0.7 3.4 ± 1.0 <0.001
HDL-cholesterol (mmol/l) 1.4 ± 0.3 1.7 ± 0.6 <0.001
Triglycerides (mmol/l) (median(IQR)) 1.4 (1.1;2.0) 1.2 (0.9;1.6) <0.05
Office systolic BP (mmHg) 126 ± 12 132 ± 14 <0.01
Office diastolic BP (mmHg) 79 ± 8 84 ± 10 <0.001
Office pulse pressure (mmHg) 47 ± 10 48 ± 10 0.73
Office mean arterial pressure (mmHg) 95 ± 8.3 100 ± 11 <0.01
Office heart rate (beats/min) 66 ± 10 62 ± 10 <0.01
24-h ABPM systolic BP (mmHg) 126 ± 11 125 ± 12 0.40
24-h ABPM diastolic BP (mmHg) 75 ± 8 76 ± 8 0.26
24-h ABPM pulse pressure (mmHg) 52 ± 9 49 ± 9 <0.05
24-h ABPM mean arterial pressure (mmHg) 92 ± 8 93 ± 8 0.86
24-h heart rate (beats/min) 74 ± 10 68 ± 9 <0.01
Creatinine (μmol/liter) 72 ± 14 76 ± 14 <0.01
Estimated GFR (mL/min/1.73 m2) (median(IQR)) 75 (66;87) 70(63;78) <0.01
Urine albumine/creatinine ratio (mg/mmol) (median(IQR)) 0.40 (0.28;0.98) 0.25 (0.17;0.40) <0.001
Carotid-femoral pulse wave velocity (m/s) 9.3 ± 2 8.0 ± 1.6 <0.001
IQR Inter Quartile Range, LDL Low Density Lipoprotein, HDL High Density Lipoprotein, BP Blood Pressure, ABPM Ambulatory Blood Pressure Monitoring, GFR
Glomerular Filtration Rate. History of cardiovascular disease: Previous acute myocardial infarction, percutaneous cardiac intervention, coronary bypass or stroke.
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metformin, 101 ± 34 vs 104 ± 34 μg/mL (women vs
men), p = 0.85.
Fibulin-1 and PWV
In unadjusted analysis of the total study sample, fibulin-
1 was not associated with PWV, p = 0.46. To adjust for
confounding from gender in the control group and from
diabetes, these parameters, with the interaction term
diabetes x gender, were included in the model. With this
adjustment, fibulin-1 was significantly associated with
PWV, which increased 0.11 ± 0.05 m/s pr 10 μg/mL in-
crease in plasma fibulin-1, p < 0.05. The association
remained in a fully adjusted model including age, gender,
mean blood pressure, heart rate, body mass index, dia-
betes, diabetes x gender and glomerular filtration rate.
In this adjusted model, a 10 μg/mL increase in plasma
fibulin was associated with 0.09 ± 0.04 m/s increase inPWV, p < 0.05. Inclusion of history of hypertension or
history of cardiovascular disease did not alter the results
of the analysis. The effect of metformin and the inter-
action term metformin × diabetes could not be assessed
in this model due to collinearity between metformin and
diabetes. Testing for interaction between diabetes and
fibulin in this model showed borderline significance,
p = 0.07. Therefore, the diabetes and control group
was also evaluated separately.
In univariate regression analysis, plasma fibulin-1 was
associated with PWV in the diabetes group, but not in
the control group, Table 3 and Figure 2. The association
between fibulin-1 and PWV remained significant in the
diabetes group in multivariate regression analysis after
adjustment for age, gender, mean arterial office BP, resting
heart rate, body mass index and estimated glomerular fil-
tration rate, Table 3. Additional adjustment for metformin
did not change this association, Table 3. Inclusion of
Table 2 Univariate associations between plasma fibulin-1 concentrations and clinical variables in 90 patients with type
2 diabetes and 90 gender- and age-matched controls
Type 2 diabetes patients Controls
(n = 90) (n = 90)
β ± SE pr μg/mL
plasma fibulin-1
P-value β ± SE pr μg/mL
plasma fibulin-1
P-value
Age (years) 0.5 ± 0.3 0.10 0.12 ± 0.32 0.71
HbA1c (%) −3.8 ± 4.7 0.42 9.3 ± 9.3 0.32
Body Mass Index (kg/m2) −1.1 ± 0.6 0.10 −0.01 ± 0.81 0.99
Plasma total cholesterol (mmol/l) 0.59 ± 3.84 0.88 2.33 ± 3.10 0.45
Plasma creatinine (μmol/liter) 0.24 ± 0.21 0.25 −0.41 ± 0.22 0.07
Estimated glomerular filtration rate (mL/min/1.73 m2) −0.40 ± 0.19 <0.05 −0.11 ± 0.25 0.65
Ln-transformed Urine albumine/creatinine ratio (mg/mmol) 1.83 ± 3.10 0.55 4.26 ± 3.8 0.27
Office systolic BP (mmHg) −0.06 ± 0.18 0.74 −0.14 ± 0.18 0.43
Office diastolic BP (mmHg) −0.33 ± 0.35 0.36 −0.34 ± 0.32 0.28
Office pulse pressure (mmHg) 0.04 ± 0.23 0.86 −0.07 ± 0.26 0.80
Office heart rate (beats/min) 0.01 ± 0.20 0.98 −0.15 ± 0.34 0.66
24-h ABPM systolic BP (mmHg) −0.31 ± 0.28 0.26 −0.13 ± 0.28 0.63
24-h ABPM diastolic BP (mmHg) −0.78 ± 0.40 0.053 −0.24 ± 0.43 0.58
24-h ABPM pulse pressure (mmHg) 0.08 ± 0.36 0.82 −0.07 ± 0.38 0.86
24-h ABPM heart rate (beats/min) 0.22 ± 0.32 0.70 −0.40 ± 0.34 0.25
SE Standard Error, BP Blood Pressure, ABPM Ambulatory Blood Pressure Monitoring.
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ease did not alter the results of the analysis. The associ-
ation between fibulin-1 and PWV did not become
significant in the control group in multivariate regression
analysis with adjustment for the above mentioned
covariates.
Discussion
The first major finding of this study was a significant as-
sociation between plasma fibulin-1 levels and PWV in
patients with type 2 diabetes and gender- and age mat-
ched controls when adjusted for effect-modification
from gender and diabetes. In stratified analysis, the asso-
ciation remained significant only in the diabetes group.
However, as testing for interaction between diabetes and
fibulin-1 was only borderline significant, no firm conclu-
sions regarding differences in the strength of the associ-
ation between PWV and fibulin-1 in the diabetes group
versus the control group can be made in the present
study. To the best of our knowledge, we are the first to
demonstrate such an association. This suggest that, even
though the association was modest, fibulin-1 might be
involved in the pathophysiological processes underlying
arterial stiffening.
A second major finding was that plasma fibulin-1
levels were lower in patients with type 2 diabetes com-
pared with controls. The finding indicated, that the ab-
solute plasma levels of fibulin-1 could not be interpretedas a simple marker of arterial stiffness, as PWV was
higher in the diabetic group compared with the controls.
The finding of low plasma fibulin-1 in diabetic patients
was unexpected, as a previous study by Cangemi et al
[11] reported markedly higher levels of plasma fibulin-1
in patients with type 2 diabetes than in non-diabetics.
Plasma fibulin-1 levels should thus be interpreted in the
context of potential confounding factors. Differences in
duration of diabetes, gender distribution and anti-
diabetic medication in the two studies may account for
the observed discrepancies. The diabetes duration was
not reported in the Cangemi study [11], but was prob-
ably longer in the older type 2 diabetic patients than in
the present study population, and accordingly these pa-
tients may have had more severe arterial alterations than
our patients. Secondly, we and others [23] found higher
plasma fibulin-1 in non-diabetic females compared with
males. The gender distribution (female/male) in the
study by Cangemi et al [11] was 5/31 in the control
group, whereas it was 44/46 in the present study. Thus,
had more females been represented in the study by
Cangemi et al [11], the plasma fibulin-1 level in the con-
trol population might have been higher and the differ-
ence between the diabetes and control group less
pronounced. Thirdly, metformin-treated patients in our
study had significantly lower fibulin-1 levels than pa-
tients not receiving metformin. The patients in the study
by Cangemi et al [11] were referred for coronary bypass
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Figure 1 Plasma fibulin-1 in patients with type 2 diabetes and gender- and age-matched controls. Horizontal line indicates mean. Panel
A: Plasma fibulin-1 in 90 patients with type 2 diabetes and 90 gender- and age-matched controls. Subgroup analyses in panel B and C: Panel B:
Plasma fibulin-1 in the 34 diabetes patients not receiving metformin and their 34 gender- and age- matched controls. Panel C: Plasma fibulin-1 in
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min treatment before the surgical procedure when the
blood samples were drawn. The patients in the present
study were in ongoing metformin treatment. As our
observations are cross-sectional, causality cannot be in-
ferred, yet if metformin had an effect on plasma fibulin-
1 and this effect tapered off as the metformin was
metabolized, even the short pause in relation to the sur-
gical procedure may have raised fibulin-1 levels in theTable 3 Association of carotid-femoral pulse wave velocity an
gender and age-matched controls
Pulse wave velocity (m/s) Type 2 diabetes patients (n
Coefficient ± SE pr 10 μg/mL
increase in plasma fibulin-1
Unadjusted 0.16 ± 0.07
Adjusteda 0.13 ± 0.06
Fully adjustedb 0.13 ± 0.06
SE Standard Error. aAdjusted for age, sex, mean arterial office blood pressure, restin
bAdjustment for the covariates in a plus metformin.diabetes group in the study by Cangemi et al [11] to un-
treated values, whereas it remained lowered in our study.
Clearly, this hypothesis remains speculative given our
study design and requires further testing in an experi-
mental setting. Metformin-treatment could potentially
also be associated with changes in PWV or other arterial
stiffness indices. A recent study found metformin treat-
ment lowered the augmentation index in patients with
non-alcohol fatty liver disease [24]. Yet, regarding PWV,d plasma fibulin-1 in patients with type 2 diabetes and
= 90) Controls (n = 90)
p Coefficient ± SE pr 10 μg/mL
increase in plasma fibulin-1
p
<0.05 0.021 ± 0.057 0.70
<0.05 0.027 ± 0.041 0.52
<0.05 -
g heart rate, body mass index and estimated glomerular filtration rate.
r=0.23, p=0.03
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Figure 2 Scatter-plots of plasma fibulin-1 and carotid femoral pulse wave velocity. r = Pearson’s correlation coefficient.
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liver disease [25] and with polycystic ovary syndrome
[26,27] have reported conflicting results regarding
metformin’s ability to lower PWV, and we did not find
any association between metformin treatment and PWV.
A third finding was the lack of association of fibulin-1
with Hba1c and the traditional cardiovascular risk fac-
tors cholesterol levels and BP indices including pulse
pressure. This is also in contrast with findings in the
study by Cangemi et al [11] and a recent study by
Scholze et al in patients with end-stage renal disease
[28], where significant associations were observed be-
tween fibulin-1 and fasting plasma glucose, HbA1c,
blood pressure and also plasma creatinine. It could thus
be hypothesized, that the association of plasma fibulin-1
with HbA1c and BP becomes evident only after a certain
disease duration with accumulated damage to the arte-
rial wall caused by longer hyperglycemic and hyperten-
sive exposure, whereas PWV might be a more sensitive
indicator of arterial stiffening and hence could be associ-
ated with fibulin-1 levels even in the early stages of the
disease. Cangemi et al also found fibulin-1 to be associ-
ated with carotid compliance, stroke volume/pulse
pressure ratio, left atrial volume index and plasma NT-
proBNP [11] and Scholze found fibulin-1 associated with
plasma fibrinogen, plasma urea and unadjusted augmen-
tation index [28], factors not assessed in the present
study. We cannot exclude, that adjustment for these pa-
rameters might have changed the results of our analysis.
PWV was recorded under standardized examination
conditions. The most important parameters to take into
account when assessing PWV are age, blood pressure
and heart rate [29]. Obesity may affect distance mea-
surement. These parameters were adjusted for in the
multivariate analyses.The present findings extend previous research on the
pathophysiological basis of the increased arterial stiffness
found in patients with diabetes. Increased brachial-radial
PWV in diabetic patients was demonstrated in 1962 [30]
and interpreted as an expression of increased diabetic
atherosclerosis burden. However, whereas the patchy in-
timal atherosclerotic lesions may contribute to arterial
stiffness, atherosclerosis-independent changes in the
ECM of the media layer also play a pivotal role for the
increased arterial stiffness seen in diabetic patients. In-
creased amounts of advanced glycosylation end-products
(AGEs) [5], fibronectin [6], type IV collagen [8] and
hyaluronan [7] have been found in the ECM of non-
atherosclerotic aortic specimens from diabetic patients
compared with non-diabetics. Conversely, decreased
content of elastin [9] and increased content of the
elastin-cleaving metalloproteinase matrix
metallopeptidase 2 [10] has been reported. These chan-
ges all contribute to increase arterial stiffness, yet the
pathophysiology remains elusive. First recently, fibulin-1
has been associated with arterial alterations in diabetes
patients [11]. It is known that fibulin-1 binds elastin
[31], fibronectin [32] and proteoglycans [33], yet, the
exact role of fibulin-1 in the arterial wall for arterial
stiffness remains to be elucidated. The present findings
extend on previous observations by the demonstration
of an independent association between plasma fibulin-1
levels and carotid-femoral PWV, the gold standard
method for assessment of arterial stiffness [3], in pa-
tients with recently diagnosed type 2 diabetes. However,
due to the cross-sectional design, we cannot infer caus-
ality of the observed association between plasma fibulin-
1 levels and PWV. Neither can the correspondence
between arterial wall fibulin-1 and plasma fibulin-1 be
assessed in this study.
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[34] in future studies might provide information regar-
ding the existence of a causal biological association
between fibulin-1 and arterial stiffness. This approach is
used to make assessment of causality from observational
data based on genetic variation [34,35]. A recent study
reported association between a genetic marker for fibulin-
2 and hypertension [36], lending support to the hypothesis
that members of the fibulin family could be causally in-
volved in arterial wall changes.
In conclusion, plasma fibulin-1 was independently
associated with increased PWV in a sample of well-
regulated patients with recently diagnosed type 2 diabetes
and gender- and age-matched controls. Fibulin-1 might
thus be involved in the pathophysiological processes
underlying stiffening of the arterial wall. However, the
plasma fibulin-1 level is not a simple marker of the degree
of arterial stiffening, as evidenced by lower plasma fibulin-
1 concentrations in the diabetes patients. Furthermore,
the observed association with metformin treatment and
gender confers complexity when making correlative inter-
pretations of data employing plasma fibulin-1 levels.
These observations reflect the complex pathophysi-
ology of arterial stiffening and underline the need for
further studies to determine the exact role of fibulin-1 in
arterial stiffness and cardiovascular risk.
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